On Thursday, Hecla Mining Co. (NYSE:HL)’s shares declined -1.55%, and closed at $3.18.
Formerly on March 27, Hecla Mining Corporation, declared that they have reached a merger contract following which Hecla will attain Revett. In the projected merger, each outstanding ordinary share of Revett will be exchanged for 0.1622 of a ordinary share of Hecla. Based on Hecla’s closing price of $3.23 on March 25, 2015 (the day preceding to signing of the contract), this represents a 32% premium to Revett’s 20-day VWAP (volume weighted average price) through March 25, 2015. The parties presently expect the transaction to close late in the second quarter, 2015. The transaction is subject to approval by Revett shareholders and to the satisfaction of other closing conditions contained in the merger contract.
Following closing of the merger, Hecla intends to continue to advance permitting of the Rock Creek project. Located in Northwest Montana, Rock Creek is considered one of the largest undeveloped silver and copper deposits in North America. Revett has stated inferred resources of 229 million ounces of silver and 2.0 billion pounds of copper. The project is about 50 miles north of Hecla’s Lucky Friday Mine in Idaho. A Supplemental Environmental Influence Statement (SEIS) is in process and the U.S. Forest Service plan indicates that the SEIS will be issued later this year for public comment.
Hecla Mining Corporation, together with its auxiliaries, discovers, attains, develops, produces, and markets precious and base metal deposits worldwide. The corporation offers unrefined gold and silver bullion bars to precious metals traders; and lead, zinc, and bulk concentrates to custom smelters and brokers.
Micron Technology, Inc. (NASDAQ:MU)’s shares dropped -1.49%, and settled at $26.73, during the last trading session on Thursday, as semiconductor solutions provider company, declared results of operations for its second quarter of fiscal 2015, which ended March 5, 2015. Proceeds for the second quarter of fiscal 2015 (a 13-week fiscal quarter) were $4.17 billion and were 9 percent lower contrast to the first quarter of fiscal 2015 (a 14-week fiscal quarter) and 1 percent higher contrast to the second quarter of fiscal 2014. Cash flows from operations were $1.25 billion for the second quarter of fiscal 2015. The first quarter of fiscal 2015 comprised of an additional week, consistent with the corporation’s 52/53 week fiscal year. On a normalized basis, proceeds for the second fiscal quarter of 2015 were down 2 percent sequentially.
“Micron posted another solid quarter in our fiscal Q2 2015,” said Micron CEO Mark Durcan. “We are happy with our progress on technology and product migrations and remain confident in the performance of our business.”
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The corporation manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
At the end of Thursday’s trade, Apollo Education Group, Inc. (NASDAQ:APOL)’s shares dipped -1.42%, and closed at $18.44, as University of Phoenix, a partner of Apollo Education Group, and the (ISC)²® Foundation declared they are offering 10 full-tuition scholarships for undergraduate and graduate students pursuing degrees in the cybersecurity field. The opportunity for qualified and educated security professionals is predictable to be very high, with employment of security analysts projected to grow by 37 percent from 2012 to 2022.
(ISC)² and University of Phoenix work with industry leaders to identify and advance the skills of IT and security professionals to assist reduce the shortage of qualified people in these fields.
Applications for the University of Phoenix/(ISC)² Foundation Cybersecurity Scholarships are presently being accepted. The deadline to apply is June 2, 2015. Each scholarship recipient will have the opportunity to complete an undergraduate or master’s degree program at University of Phoenix and can choose to attend a local University of Phoenix campus or online. (ISC)² will also provide recipients with a voucher to take either the SSCP® or CISSP® certification exam within one year of graduation. The exam voucher will be offered to the awarded recipients upon proof of graduation in an area of study with an emphasis on cybersecurity and/or information assurance.
Apollo Education Group, Inc. provides private education services. It offers online and on-campus undergraduate, graduate, professional development, and other non-degree educational programs and services primarily to working learners in the United States and internationally.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), ended its Thursday’s trading session with -1.39% loss, and closed at $9.96, as last Monday, ZIOPHARM and Intrexon Corporation (XON) declared their oncology programs will be strengthened through Intrexon’s new global partnership focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, counting upfront payment, milestones and royalties, equally with ZIOPHARM.
Under the partnership Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its contract with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM’s other oncology programs will continue through its Exclusive Channel Partnership(ECC) with Intrexon.
ZIOPHARM Oncology, Inc., a biotechnology corporation, focuses on acquiring, developing, and commercializing cancer therapies. The corporation is employing novel gene expression, and control and cells technologies to deliver cell-based therapies for the treatment of cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
